RECEIVED CENTRAL FAX CENTER

MAY 1 8 2004

AMGEN Amgen Inc.

Amgen Inc.
Law Department
1201 Amgen Court West
Seattle, WA 98119

Telephone: Facsimile:

(206) 265-7847 206-233-0644

e-mail:

fowlerk@amgen.com

FAX MESSAGE - PLEASE DELIVER IMMEDIATELY

Send to:

United States Patent Office

FAX: 703-872-9306

ATTN: TC1600

From:

Kathleen Fowler

Date: May 18, 2004

Senior Counsel/Patent Attorney

206-265-7000 Ext. 57847

No, of pages including this page:

16

Re:

US Patent Application Serial No. 10/001,848

Filed: November 20, 2001

ACTUADO A

METHODS OF USING IMXP-888 AND

IMXP-888 ANTAGONISTS

The following documents are being facsimile transmitted to the USPTO, ATTN: TC1600:

3 Month Extension of Time (1 page + copy); Amendment and Response (13 pages)

If transmission problems occur contact Kathleen Prindle at 206-265-7420.

CONFIDENTIALITY NOTICE: This communication (including any accompanying page(s)) is intended solely for the use of the individual or entity named above and may contain information that is privileged, confidential or exempt from disclosure under applicable law. If the reader of this communication is not the intended recipient, you are hereby notified that any copying, distribution or other unauthorized use of this communication is prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message to us at the above address via the U.S. Postal Service. Thank you.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of: Chipman et al.

Docket No.:

3081-A

Serial No.:

10/001,848

Group Art Unit:

1644

Filing Date:

November 21, 2001

Examiner: Belyavskyi, Michael

METHODS OF USING IMNP-888 AND IMXP-888 ANTAGONISTS

AMENDMENT AND RESPONSE

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

In response to the Office Action dated November 19, 2003, please amend the aboveidentified application as follows:

Amendments to the Claims are reflected in the listing of claims that begins on page 2 of this paper.

Remarks begin on page 5 of this paper.